1st line Relapsed or Metastatic mucosal, HNSCC, not NPC

Treatment

HPV(+)

- HLA matched
  - PDL1(+)
    - ENT0073 Phase I CUE-101 Monotherapy in HPV+ Recurrent Metastatic Head & Neck Squamous Cell Carcinoma (HNSCC)
      - PI: Colevas
        - Gilead Sciences, Inc.
- PDL1(+)
  - ENT0084 Phase II Pembrolizumab +/- BNT111 in HNSCC Which is HPV16+ and Expresses PD-L1
    - PI: Colevas
      - BioNTech SE
- PDL1(-)
  - ENT0088 Phase II Magrolimab Combination Therapy in Head and Neck Squamous Cell Carcinoma
    - PI: Colevas
      - Gilead Sciences, Inc.

Prior ICI Injectable lesions

HPV(-)

- Any PDL1
  - ENT0088 Phase II Magrolimab Combination Therapy in Head and Neck Squamous Cell Carcinoma
    - PI: Colevas
      - Gilead Sciences, Inc.

KEY

- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu